Clinical Trials Logo

Staphylococcal Skin Infections clinical trials

View clinical trials related to Staphylococcal Skin Infections.

Filter by:

NCT ID: NCT00513799 Completed - Clinical trials for Staphylococcus Aureus

The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

StLStaRS
Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the natural history of community-associated Staphylococcus aureus infections in both adult and pediatric patients by monitoring the rate of recurrent infections in those colonized with S. aureus. In addition, this study will evaluate the efficiency of commonly prescribed decolonization measures in patients presenting with S. aureus skin and soft tissue infections.

NCT ID: NCT00492271 Terminated - Clinical trials for Community Acquired Pneumonia

First Time in Man Trial for Friulimicin B

Start date: June 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to study the safety of single doses and multiple doses of Friulimicin B in healthy volunteers. The level of Friulimicin B will be measured in the subjects blood and urine. One part of the study will assess if Friulimicin B in the plasma of subjects has activity against bacteria.

NCT ID: NCT00475930 Completed - Clinical trials for Staphylococcus Aureus

Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates

Start date: May 2007
Phase: N/A
Study type: Interventional

Outbreaks of skin and soft tissue infections (SSTI) related to community associated Methicillin-resistant Staphylococcus aureus (MRSA) have become increasingly common in military training units. Risk factors for MRSA related SSTI such as crowding, poor hygiene and shared equipment are often hard to avoid in a military training environment, often designed to simulate battlefield conditions. It has recently been demonstrated that military recruits colonized with MRSA may be at increased risk of developing SSTI. Studies in the hospital environment have shown that decolonizing inpatients known to carry MRSA decreases the rates of MRSA related infections in the treated individuals and also in their inpatient unit as a whole. The investigators propose a randomized, double blind, placebo controlled trial to: 1. Evaluate the effectiveness, feasibility, and safety of chlorhexidine body cloths, self-administered three times weekly, in preventing SSTI among recruits in military training facilities; and 2. Evaluate the effectiveness of chlorhexidine body cloths in decreasing rates of Staphylococcus aureus colonization among military recruits.

NCT ID: NCT00463801 Terminated - Clinical trials for Staphylococcal Skin Infections

Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

Start date: January 2007
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults

NCT ID: NCT00442832 Completed - Clinical trials for Staphylococcal Skin Infection

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.

NCT ID: NCT00352612 Completed - Abscess Clinical Trials

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.

NCT ID: NCT00228982 Completed - Clinical trials for Skin Diseases, Infectious

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.

NCT ID: NCT00210899 Completed - Clinical trials for Skin Diseases, Infectious

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections. The study will also characterize the safety and tolerability of treatment with ceftobiprole medocaril in patients with complicated skin and skin structure infections.

NCT ID: NCT00107978 Completed - Clinical trials for Staphylococcal Skin Infection

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

ATLAS2
Start date: February 2005
Phase: Phase 3
Study type: Interventional

Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.

NCT ID: NCT00091819 Completed - Clinical trials for Staphylococcal Skin Infection

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

ATLAS1
Start date: January 2005
Phase: Phase 3
Study type: Interventional

Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.